Tag Archives: Logos Capital

Olema Adds $54M to Start Human Tests of Breast Cancer Drug Candidate

Olema Oncology has raised $54 million to advance its lead drug candidate into human tests, having been working in stealth since 2007 to develop a daily pill to treat women with breast cancer whose disease is driven by the hormone estrogen. San Francisco-based Olema announced Wednesday that the Series B financing round will allow it to start […]

Posted in National blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , | Comments Off on Olema Adds $54M to Start Human Tests of Breast Cancer Drug Candidate

VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs

Dave Johnson has known UC San Diego physician and cancer reseacher Thomas Kipps for nearly 20 years. Now Johnson, CEO of San Diego-based cancer drug developer VelosBio, has secured $137 million to accelerate the company’s goal of developing targeted therapies based on an antibody program developed by Kipps that homes in on tumors with a […]

Posted in National blog main, San Diego, San Diego blog main, San Diego top stories, San Francisco blog main, Seattle blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs

Annexon Adds On $100M to Advance Antibodies to Treat Neurodegeneration

Annexon Biosciences, a biotech founded in late 2014 by former Elan Pharmaceuticals executives, has added $100 million to its coffers to move its two clinical-stage programs along and to continue advancing its preclinical pipeline. The South San Francisco-based company is developing drugs for patients with autoimmune and neurodegenerative disorders that are caused by an abnormal […]

Posted in National blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , | Comments Off on Annexon Adds On $100M to Advance Antibodies to Treat Neurodegeneration

C4 Therapeutics Adds $170M to Test Protein Degraders in the Clinic

C4 Therapeutics, a biotech developing small molecules designed to take advantage of a cellular mechanism as a way to treat disease, has raised $170 million in venture equity and debt to start human testing. The Watertown, MA-based firm is among a number of companies competing in the popular protein degradation space, in which drug developers […]

Posted in Boston, Boston blog main, Boston top stories, National blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on C4 Therapeutics Adds $170M to Test Protein Degraders in the Clinic

Novartis Leads $100M Round for Fibrosis-Focused Pliant Therapeutics

When Novartis signed on as a partner to Pliant Therapeutics last fall, it also agreed to eventually take an equity stake in the smaller biotech. The Swiss pharmaceutical giant made good on that commitment Tuesday, leading a $100 million investment. Besides Novartis, the Series C round of funding adds so-called crossover investors, firms that invest […]

Posted in Boston blog main, Boston top stories, National blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Novartis Leads $100M Round for Fibrosis-Focused Pliant Therapeutics

Avidity Bio Adds $100M to Advance R&D of Muscle Disorder Drugs

Earlier this year, Avidity Biosciences and Eli Lilly began a partnership to develop new drugs based on the biotech’s technology for delivering genetic material to cells. On Wednesday, Lilly was among a group of investors that joined a $100 million financing for the company. The funding, a Series C round, was led by RTW Investments. […]

Posted in Indiana blog main, Indiana top stories, National blog main, San Diego, San Diego blog main, San Diego top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Avidity Bio Adds $100M to Advance R&D of Muscle Disorder Drugs